Abiopharma

PMGC HOLDINGS INC. (ELAB) Announces Clinical Trial Update PMGC HOLDINGS INC. (ELAB) provided an update on its clinical development programs. Clinical Development Highlights:

• Clinical Stage: Phase III
• Collaboration: Development and License Agreement
  • targeting aging-related pathways. Its proprietary MitoNova™ AI-powered platform integrates biological, chemical, and mitochondrial-function datasets to accelerate the discovery of compounds with the potential to improve cellular processes and overall tissue health. Multiple products incorporating compounds discovered by Yuva Biosciences are already on the market, including Revive+ by BosleyMD, MitoActive by Arata, and Core100 by Rerise Health. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information, please visit www.yuvabio.com. About NorthStrive Biosciences Inc. NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address the issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995